FDA Bans Oscar Bobo for Five Years Over Mislabeled Drug Imports
Published Date: 5/15/2026
Notice
Summary
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Five‑Year Drug Import Debarment
Oscar Bobo is banned for 5 years from importing or offering to import any drug into the United States, effective May 15, 2026. FDA found that between April 5, 2019 and September 3, 2024 he imported or offered for import 8 parcels containing 10 products (5,970 tablets) that were misbranded, and he waived his right to a hearing by not responding by March 25, 2026. Mr. Bobo may apply at any time for termination of the debarment under section 306(d)(1) of the FD&C Act by submitting an application as directed in the notice.
Importing for Debarred Person Is Prohibited
During Mr. Bobo's 5-year debarment, importing or offering for import any drug "by, with the assistance of, or at the direction of" Oscar Bobo is a prohibited act under section 301(cc) of the FD&C Act, effective May 15, 2026. That prohibition applies to conduct during the debarment period and may expose anyone who assists or acts at his direction to enforcement consequences.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09268 — Postapproval Pregnancy Safety Studies; Guidance for Industry; Availability
The FDA just released final guidance to help drug makers study how their medicines affect pregnant women after approval. This update affects companies and researchers who must now follow clearer steps to check pregnancy safety, helping protect moms and babies. The guidance is effective immediately, with no new costs announced, but it encourages better, safer studies going forward.
Previous / Next Documents
Previous: 2026-09766 — Notice of Final Federal Agency Actions on Proposed Transportation Project in State Florida
Florida’s Department of Transportation is ready to upgrade Clearlake Road from a two-lane street to a safer, four-lane road with a cool new roundabout and bike-friendly paths on both sides. If you want to challenge these changes, you’ve got until October 13, 2026, to speak up. This project promises smoother traffic and better travel for everyone in the area!
Next: 2026-09768 — Notice of Determinations; Culturally Significant Objects Being Imported for Exhibition-Determinations: “Tarot! Renaissance Roots, Modern Visions” Exhibition
The U.S. government has approved special Tarot art pieces from other countries to be shown temporarily at The Morgan Library & Museum in New York and possibly other places. This means the exhibition is officially recognized as important to culture and the nation. No costs or deadlines affect the public, but the show highlights cool Renaissance and modern Tarot art for everyone to enjoy.